CD4 MOLECULE BELONGS TO THE PHENOTYPIC REPERTOIRE OF MOST CASES OF ACUTE MYELOID LEUKEMIA (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CD4 MOLECULE BELONGS TO THE PHENOTYPIC REPERTOIRE OF MOST CASES OF ACUTE MYELOID LEUKEMIA (MEETING ABSTRACT)

Haematologica; 76(Suppl 4):12 1991. Unique Identifier : AIDSLINE ICDB/92680352
Rigo A; Vinante F; Vincenzi C; Castaman G; Cassatella M; Pizzolo G; Cattedra di Ematologia, Univ. of Verona, Italy

Abstract: The CD4 molecule is a single-chain transmembrane glycoprotein of 55 kD expressed on a broad range of cell populations, including thymocytes, peripheral T subsets (helper/inducer T cells), monocytes, histiocytes and microglial cells. CD4 is the receptor for class II molecules and HIV; its cytoplasmic domain is associated with a protein-tyrosine kinase p56lck; on CD4+ lymphocytes it regulates the function of CD3/TCR complex. The wide range of cellular expression of CD4 molecule prompted us to investigate its possible presence in blast cells in acute myeloid leukemia. We studied 15 AML cases by cytofluorimetric analysis with MoAb Leu3 PE and by total cellular RNA extraction, Northern blot and hybridization with a specific probe. We found that the majority of investigated cases (12/15) expressed full-length CD4 mRNA according to immunophenotyping data presented in a table. Thus, AML blast cells we studied can transcribe, translate and express on their cell surface the CD4 molecule, which might be considered to belong to their phenotypic repertoire.

Keywords: Antigens, CD4/GENETICS/*IMMUNOLOGY/METABOLISM Gene Expression Histocompatibility Antigens Class II/IMMUNOLOGY Human HIV Antigens/IMMUNOLOGY Immunoglobulins, Fab/IMMUNOLOGY Immunophenotyping Leukemia, Myelocytic, Acute/*IMMUNOLOGY Protein-Tyrosine Kinase/IMMUNOLOGY Receptors, Antigen, T-Cell/IMMUNOLOGY RNA, Messenger/METABOLISM Transcription Factors/IMMUNOLOGY ABSTRACT
920630
M9261013

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .